Investor's Business Daily on MSN
Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win
Viking Therapeutics stock fell Wednesday after the company said it overenrolled one of its final-phase studies for its weight ...
The MarketWatch News Department was not involved in the creation of this content. VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN ...
Discover why Viking Therapeutics, Inc. surged 50% as GLP-1 market buzz and strong VK2735 results renew investor optimism.
Todd Young was first to speak at Monday’s Holmen School Board meeting. A parent, he said that the state-sponsored SAGE program at Viking Elementary keeps class sizes small and allowed his third-grade ...
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback